Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic Cartibeads is a bio-engineered cartilage graft developed by Vanarix for the treatment of cartilage lesions and early osteoarthritis. The product consists of small, bead-shaped mini-grafts (approximately 1.5 mm in diameter) produced from allogeneic articular chondrocytes. These chondrocytes are aggregated and embedded within a self-secreted hyaline-like matrix rich in collagen type II and glycosaminoglycans (GAG). Unlike traditional cell therapies that require a scaffold, Cartibeads are scaffold-free and designed to be implanted directly into cartilage defects to promote regeneration. The allogeneic version utilizes donor cells, allowing for an off-the-shelf or standardized approach compared to the autologous version.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic cartibeads.